Evidence map›Paper›PMID 34837148›Full record

ArticleMolecular biology reports2022

The link of ERCC2 rs13181 and ERCC4 rs2276466 polymorphisms with breast cancer in the Bangladeshi population.

Shaid All Sahaba, Mohammad Abdur Rashid, Md Saiful Islam, Noor Ahmed Nahid, Mohd Nazmul Hasan Apu, Taposhi Nahid Sultana, Nusrat Islam Chaity, Md Mehedi Hasan, Mohammad Safiqul Islam

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. The association of rs25487 of theBiomolecules & biomedicine · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shaid All SahabaDepartment of Pharmacy, State University of Bangladesh, Dhaka, Bangladesh.
Mohammad Abdur RashidDepartment of Pharmaceutical Chemistry, University of Dhaka, Dhaka, Bangladesh. r.pchem@yahoo.com.ORCID http://orcid.org/0000-0003-1464-7115
Md Saiful IslamDepartment of Clinical Pharmacy and Pharmacology, University of Dhaka, Dhaka, Bangladesh.
Noor Ahmed NahidDepartment of Clinical Pharmacy and Pharmacology, University of Dhaka, Dhaka, Bangladesh.
Mohd Nazmul Hasan ApuDepartment of Clinical Pharmacy and Pharmacology, University of Dhaka, Dhaka, Bangladesh.
Taposhi Nahid SultanaDepartment of Clinical Pharmacy and Pharmacology, University of Dhaka, Dhaka, Bangladesh.
Nusrat Islam ChaityDepartment of Clinical Pharmacy and Pharmacology, University of Dhaka, Dhaka, Bangladesh.
Md Mehedi HasanDepartment of Clinical Pharmacy and Pharmacology, University of Dhaka, Dhaka, Bangladesh.
Mohammad Safiqul IslamDepartment of Pharmacy, Noakhali Science and Technology University, Sonapur, Noakhali, 3814, Bangladesh. research_safiq@yahoo.com.ORCID http://orcid.org/0000-0003-4924-5319

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer (BC) is the most common disease in women and the leading cause of death from cancer globally. Epidemiological studies examined that nucleotide excision repair genes ERCC2 (rs13181) and ERCC4 (rs2276466) SNPs might increase cancer risk. Based on the previous investigation, this study was conducted to explore the correlation between these polymorphisms and BC susceptibility in Bangladeshi women. METHODS AND

resultsBetween January 2019 and January 2020, 140 blood samples were collected from female patients histologically diagnosed with BC, and 111 female controls were recruited from non-cancer subjects. Genotyping was performed applying the PCR-RFLP method, and all statistical analyzes were conducted using SPSS, version 25.0. Comparison of characteristics and clinicopathological features between ERCC2 rs13181 and ERCC4 rs2276466 carriers and non-carriers showed no significant link with BC. Analysis of ERCC2 rs13181 with the risk of BC showed that the GG genotype and G allele carriers showed a fourfold and 1.78-fold higher risk (OR 4.00, P = 0.001 and OR 1.78, P = 0.002) that are statistically significant. In addition, the patients with combined TG+GG genotype revealed a 2.09-fold increased chance (OR 2.09, P = 0.020) BC development. Analysis of recessive model (GG vs. TT+TG) also depicted 2.74-times significantly higher risk (OR 2.74, P = 0.002). On the other hand, ERCC4 rs2276466 polymorphism did not show any significant association with BC (P > 0.05).

conclusionsOur findings show that ERCC2 rs13181 is linked to an elevated risk of BC. Our study also shows that ERCC4 rs2276466 polymorphism has no substantial risk of BC in the Bangladeshi population.

Indexed as

Breast NeoplasmsAsian PeopleDNA-Binding ProteinsFemaleGenetic Predisposition to DiseaseGenotypeHumansPolymorphism, Single NucleotideXeroderma Pigmentosum Group D ProteinDNA-Binding ProteinsERCC2 protein, humanXeroderma Pigmentosum Group D Proteinxeroderma pigmentosum group F proteinBreast cancerERCC2ERCC4Genetic associationPolymorphism

Identifiers

PMID34837148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.